new outline to begin writing introdution and lit review
parent
c2243ba548
commit
5a77259f3e
@ -0,0 +1,43 @@
|
|||||||
|
In 19xx the United States Food and Drug administration was created to "QUOTE".
|
||||||
|
Since XXXX they have <Task relevant to what they do, i.e. how many drugs they have approved>.
|
||||||
|
In 2007, they began requiring that drug developers register and publish clinical trials on \url{https://clinicaltrials.gov}.
|
||||||
|
This provides a public mechanism where clinical trial sponsors are responsible to explain
|
||||||
|
what they are trying to acheive and how it will be measured, as well as provide the public the ability to
|
||||||
|
search and find trials that they might enroll in.
|
||||||
|
%this has become part of multiple datasets (cortellis) used to evaluate what drugs might be entering the market soon.
|
||||||
|
This brings up a question: can we use this public data on clinical trials to describe what effects their success or failure?
|
||||||
|
In this work, I use updates to records on \url{https://ClinicalTrials.gov} to separate the effect of
|
||||||
|
|
||||||
|
%Describe how clinical trials fit into the drug development landscape and how they proceed
|
||||||
|
Clinical trials are a required part of drug development.
|
||||||
|
Not only does the FDA require that a series of clinical trials demonstrate sufficient safety and efficacy of
|
||||||
|
a novel pharmaceutical compound or device, producers of derivative medicines may be required to ensure that
|
||||||
|
their generic small molecule compound -- such as ibuprofen or levothyroxine -- matches the
|
||||||
|
performance of the originiator drug if delivery or dosage is changed.
|
||||||
|
For large molecule generics (termed biosimilars) such as Adalimumab
|
||||||
|
(Brand name Humira, with biosimilars Abrilada, Amjevita, Cyltezo, Hadlima, Hulio,
|
||||||
|
Hyrimoz, Idacio, Simlandi, Yuflyma, and Yusimry),
|
||||||
|
the biosimilars are required to prove they have similar efficacy and safety to the
|
||||||
|
reference drug.
|
||||||
|
|
||||||
|
When registering these clinical trials
|
||||||
|
% discuss how these are registered and what data is published.
|
||||||
|
% Include image and discuss stages
|
||||||
|
% Discuss challenges faced
|
||||||
|
|
||||||
|
% Introduce my work
|
||||||
|
|
||||||
|
At least in the world of drug development, these trials take place in a wider framework of Phases
|
||||||
|
% Now talk about phases, begin introducing work by Chris Adams
|
||||||
|
% Lead into lit review
|
||||||
|
|
||||||
|
|
||||||
|
% Causality
|
||||||
|
|
||||||
|
% Data
|
||||||
|
|
||||||
|
% Economic Model
|
||||||
|
|
||||||
|
% Results
|
||||||
|
|
||||||
|
% Conclusion
|
||||||
Loading…
Reference in New Issue